Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier

被引:50
作者
Hewitt, M. [1 ]
Madden, J. C. [1 ]
Rowe, P. H. [1 ]
Cronin, M. T. D. [1 ]
机构
[1] Liverpool John Moores Univ, Sch Pharm & Chem, Liverpool L3 3AF, Merseyside, England
关键词
reproductive toxicity; placental transfer; quantitative structure-activity relationships; clearance index; transfer index;
D O I
10.1080/10629360601053893
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The replacement of animal testing for endpoints such as reproductive toxicity is a long-term goal. This study describes the possibilities of using simple (quantitative) structure-activity relationships ((Q)SARs) to predict whether a molecule may cross the placental membrane. The concept is straightforward, if a molecule is not able to cross the placental barrier, then it will not be a reproductive toxicant. Such a model could be placed at the start of any integrated testing strategy. To develop these models the literature was reviewed to obtain data relating to the transfer of molecules across the placenta. A reasonable number of data were obtained and are suitable for the modelling of the ability of a molecule to cross the placenta. Clearance or transfer indices data were sought due to their ability to eliminate inter-placental variation by standardising drug clearance to the reference compound antipyrine. Modelling of the permeability data indicates that (Q)SARs with reasonable statistical fit can be developed for the ability of molecules to cross the placental barrier membrane. Analysis of the models indicates that molecular size, hydrophobicity and hydrogen-bonding ability are molecular properties that may govern the ability of a molecule to cross the placental barrier.
引用
收藏
页码:57 / 76
页数:20
相关论文
共 107 条
[1]  
AKBARALY JP, 1984, P 5 EUR S QUANT STRU
[2]   Ex vivo perfusion of the human placental cotyledon:: implications for anesthetic pharmacology [J].
Ala-Kokko, TI ;
Myllynen, P ;
Vähäkangas, K .
INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA, 2000, 9 (01) :26-38
[3]   Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta [J].
AlaKokko, TI ;
Pienimaki, P ;
Lampela, E ;
Hollmen, AI ;
Pelkonen, O ;
Vahakangas, K .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1997, 41 (02) :313-319
[4]   TRANSFER OF LIDOCAINE AND BUPIVACAINE ACROSS THE ISOLATED-PERFUSED HUMAN PLACENTA [J].
ALAKOKKO, TI ;
PIENIMAKI, P ;
HERVA, R ;
HOLLMEN, AI ;
PELKONEN, O ;
VAHAKANGAS, K .
PHARMACOLOGY & TOXICOLOGY, 1995, 77 (02) :142-148
[5]  
[Anonymous], 2001, WHIT PAP STRAT FUT C
[6]   Controlling drug delivery across the placenta [J].
Audus, KL .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (03) :161-165
[7]  
BARZAGO MM, 1994, J PHARMACOL EXP THER, V269, P28
[8]   DETERMINANTS OF PLACENTAL DRUG TRANSFER - STUDIES IN THE ISOLATED-PERFUSED HUMAN PLACENTA [J].
BASSILY, M ;
GHABRIAL, H ;
SMALLWOOD, RA ;
MORGAN, DJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (09) :1054-1060
[9]   Placental glucose transfer and fetal growth [J].
Baumann, MU ;
Deborde, S ;
Illsley, NP .
ENDOCRINE, 2002, 19 (01) :13-22
[10]  
Bawdon R E, 1998, Infect Dis Obstet Gynecol, V6, P244, DOI 10.1002/(SICI)1098-0997(1998)6:6<244::AID-IDOG4>3.0.CO